MEDP
Medpace Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
31.35
PEG
2.71
P/B
30.71
P/S
5.59
EV/EBITDA
25.18
DCF Value
$363.02
FCF Yield
5.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.1%
Operating Margin
21.1%
Net Margin
17.8%
ROE
118.8%
ROA
35.3%
ROIC
67.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $708.5M | $135.1M | $4.67 |
| FY 2025 | $2.53B | $451.1M | $15.28 |
| Q3 2025 | $659.9M | $111.1M | $3.87 |
| Q2 2025 | $603.3M | $90.3M | $3.10 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.39
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.